Abstract
Prevention of rheumatoid arthritis is an ambitious therapeutic goal. Once it has developed, rheumatoid arthritis is characterised by high chronicity and often requires lifelong treatment.1,2 Sustained drug-free remission is rare, especially in seropositive disease, which is defined by the presence of rheumatoid factor and anti-citrullinated protein antibodies (ACPA).3 Onset of rheumatoid arthritis, characterised by joint swelling, is preceded by a pre-arthritis phase, in which patients show discrete symptoms (eg, pain), presence of autoantibodies (rheumatoid factor and ACPA), and subclinical signs of inflammation (eg, tenosynovitis) on an ultrasound or MRI scan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
